Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
TRELSTAR (triptorelin pamoate) is a GnRH agonist administered as an intramuscular injection that suppresses luteinizing hormone and follicle-stimulating hormone. It is indicated for advanced prostate cancer and endometriosis in women. The drug works by initially stimulating then desensitizing pituitary gonadotropin receptors, resulting in sustained suppression of sex hormone production.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation and shifting focus toward brand defense and managed care strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
Worked on TRELSTAR at Verity Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TRELSTAR offers experience in a mature, defensible therapeutic franchise with entrenched market presence, but also limited growth opportunity given LOE proximity. Career progression on this product typically emphasizes managed care negotiation, competitive positioning, and market share defense rather than launch or expansion activities.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo